Silence of the LAM

Ng C. S. H., Wan S., Wan I. Y. P., Underwood M. J.

Source: Eur Respir J 2008; 32: 522-523

Journal Issue: August

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ng C. S. H., Wan S., Wan I. Y. P., Underwood M. J.. Silence of the LAM. Eur Respir J 2008; 32: 522-523

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

LAM: lymphangioleiomyomatosis Source: Breathe 2014; 10:331-332 Year: 2014
What is LAM and how should it be managed? Source: International Congress 2014 – Advances in care for patients with lymphangioleiomyomatosis (LAM) Year: 2014
Lymphangioleiomyomatosis (LAM) Source: Breathe 2017; 13: 64 Year: 2017
Long Term Sirolimus therapy for LAM: a real life experience Source: International Congress 2017 – Rare diseases Year: 2017
Pulmonary tuberculosis with polyneuro-radiculopathy: Not forget Guillain Barré syndrome! Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011
Multidrug Resistant Tuberculosis (MDR-TB) Source: CME Online 2010 Year: 2005
Management of patients with LAM Source: Annual Congress 2010 - ERS Guidelines for the diagnosis and management of lymphangioleiomyomatosis Year: 2010
Construing the role of Proteasome Accessory Factor-C in fluoroquinolone resistance in pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
The "Coil Associated Opacity" in endoscopic emphysema treatment. Friend or foe? Source: International Congress 2018 – Endoscopic lung volume reduction Year: 2018
Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM) Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Pulmonary tuberculosis control: does COVID-19 have any effect? Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Evaluation of 123 Cases with MDR TB (Multidrug Resistant Tuberculosis) Treatment Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Sporadic and TSC-related lymphangioleiomyomatosis (LAM): The experience of Ospedale San Paolo of Milan (preliminary data) Source: International Congress 2014 – ILDs 3 Year: 2014
Is pulmonary rehabilitation (PR) an effective therapy in lymphangioleiomyomatosis (LAM)? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012
Biomarkers for tuberculosis: the case for lipoarabinomannan Source: ERJ Open Res, 5 (1) 00115-2018; 10.1183/23120541.00115-2018 Year: 2019
Late Breaking Abstract - First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment For Chronic Bronchitis (CB) Source: International Congress 2018 – Interventional pulmonology highlights in 2018: latest innovations Year: 2018
Rescue! Therapy and the paradox of the Barcalounger Source: Eur Respir J 2003; 21: 916-917 Year: 2003
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019